2020 Could Spell The End Of Mega-Mergers, For Now
Instead Expect A Wave Of Mid-Sized Deals In 2020, Industry Watchers Say
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
